Hyperion DeFi, Inc. (HYPD)
HYPDNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.70
+0.1100 (+4.25%) today
Regular session, Nov 11, 3:30 PM ET
- Market cap
- $41.69m
- P/E
- –
- EPS, last 4 quarters
- $-7.61
- Dividend yield
- –
- Day range
- $2.65 to $2.79
- 52-week range
- $2.34 to $6.00
- Average volume
- 395.0k
- Previous close
- $2.59
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $9.83, +264.1% from here
Earnings
Next report Nov 12, 2026
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $303.0k | $496.0k | $244.0k | $358.0k |
| Gross profit | $303.0k | $193.0k | $244.0k | $358.0k |
| Operating income | $4.43m | -$39.77m | $8.73m | $31.01m |
| Net income | $6.63m | -$39.77m | $8.84m | $30.95m |
Last four quarters: revenue $1.40m, margin 474.8%, free cash flow –
News
8 latest- Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?The Motley Fool · 13 minutes ago
- Stocks Surge on AI Demand OptimismBarchart · 14 minutes ago
- EuroDry (EDRY) Q3 2026 Earnings Call TranscriptThe Motley Fool · 15 minutes ago
- Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?The Motley Fool · 16 minutes ago
- Elemental Royalty (ELE) Q3 2026 Earnings Call TranscriptThe Motley Fool · 17 minutes ago
- Big Sky Industrial (BSIN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 17 minutes ago
- Stocks Climb as AI Demand Worries Ease on CoreWeave EarningsBarchart · 22 minutes ago
- Reed's (REED) Q3 2026 Earnings Call TranscriptThe Motley Fool · 31 minutes ago
The company
Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of HYPE. The Company provides investors with streamlined access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility. Hyperion DeFi is also developing its proprietary Optejet User Filled Device that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- hyperiondefi.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.